Table 4.
Ref. | Side effect | Patients (n) | Study design | Impact on survival | Impact on other parameters | Predictive value |
Otsuka et al[42] | Skin reaction | 94 | Retrospective | Better OS | No impact on ORR, DCR, and TTP | No |
Vincenzi et al[45] | 65 | Retrospective | Trend to a better OS | Better DCR | Early skin toxicity could predict efficacy of sorafenib | |
Better TTP | ||||||
Di Costanzo et al[43] | 65 | Retrospective | Better OS | Not reported | Skin toxicity could predict survival | |
Shomura et al[44] | 37 | Retrospective | Better OS | Better DCR | Skin toxicity could predict efficacy | |
Reig et al[46] | 147 | Prospective | Better OS | Better TTP | Early skin reaction could predict efficacy of sorafenib and survival | |
Otsuka et al[42] | Arterial hypertension | 94 | Retrospective | No impact | No impact | No |
Estfan et al[55] | 41 | Retrospective | Better OS | Trend to better TTP |
DCR: Disease control rate; OS: Overall survival; ORR: Objective response rate; TTP: Time to progression.